Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)

Recent observational data have suggested an increased risk of cerebrovascular accidents associated with exposure to risankizumab. This article discusses these findings and highlights why there is a need for future observational studies investigating this potential signal.